Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Jochems, A.; Leeneman, B.; Franken, M.G.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; ... ; Hoeven, K.J.M. van der (2018)

Article / Letter to editor

• clinical practice
• drug use
• immune-related adverse events
• ipilimumab
• metastatic melanoma
• overall survival
• real-world outcomes

• All authors: Jochems, A.; Leeneman, B.; Franken, M.G.; Schouwenburg, M.G.; Aarts, M.J.B.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Eertwegh, A.J.M. van den; Groenewegen, G.; Groot, J.W.B. de; Haanen, J.B.A.G.; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.H.; Kruit, W.H.J.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Uyl-de Groot, C.A.; Hoeven, K.J.M. van der
• Date: 2018-07-31
• Journal: Anti-Cancer Drugs
• Volume: 29
• Issue: 6
• Pages: 572 - 578
• DOI: doi:10.1097/CAD.0000000000000629